Kalaris Therapeutics Inc
NASDAQ:KLRSBiotechnology
+$0.16 today
- Market cap
- $54.75M
- Beta
- 0.14
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$1.86
Volume 0.07M
Average 0.08M
KLRS Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Kalaris Therapeutics IncNASDAQ: KLRS
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income grows 6.5% year over year
Q1 FY2026 net income of $10.86M (cash outflow) rose 6.5% year over year. Sequentially, it rose 8.6% from the prior quarter. Over 3 fiscal years it compounded at +41.0% a year.
Context
- Net income grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate of -$27.52M (-36.7%) for the fiscal year ending Dec 2026, a slowdown from the -26.1% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$10.86M+8.6% QoQ
- Last fiscal yearDec 2025
- -$43.44M-26.1% YoY
- LTMMar 2026
- -$44.1M— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +6.5% | -3.1% | -9.5 pp |
| 1 year | -26.1% | -36.7% | -10.6 pp |
| 3-year CAGR | +41.0% | -3.6% | -44.7 pp |
| 5-year CAGR | -1.9% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (43.44M) USD
- Year-over-year change
- +26.1%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (43.44M) | +26.1% |
| FY2024 | 2024-12-31 | (58.77M) | -299.8% |
| FY2023 | 2023-12-31 | (14.7M) | +5.1% |
| FY2022 | 2022-12-31 | (15.49M) | +91.0% |
| FY2021 | 2021-12-31 | (171.96M) | — |
Net Income vs competitors
How KLRS compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Over three fiscal years its annual growth of +41.0% compares with a peer median of +2.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $153.6M USD | -37.4% | +17.0% | 154.2% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $87.07M USD | +21.4% | +12.6% | — |
| FY2025 | $55.48M USD | +255.0% | -21.8% | 86687.5% | |
| LTM Mar 2026 | $49.87M USD | -29.4% | -21.8% | 4987.4% | |
IMAImageneBio Inc | LTM Mar 2026 | $45.07M USD | +8.1% | -8.7% | — |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $44.1M USD | — | +41.0% | — |
| LTM Mar 2026 | €41.2M EUR | -7.9% | +14.1% | 140477.1% | |
| LTM Mar 2026 | $40.23M USD | +45.6% | +34.5% | — | |
| LTM Mar 2026 | $24.17M USD | -3.2% | -31.5% | 339.3% | |
| Peer median (excluding KLRS) | — | +2.4% | +2.0% | 4987.4% | |
Competitors are the stored peer set for KLRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (171.96M) | (15.49M) | (14.7M) | (58.77M) | (43.44M) |
| Depreciation & Amortization | 1.12M | 0 | 0 | 0 | 13K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 271K | 148K | 0 | 0 |
| Change in Working Capital | 19.35M | 3.4M | (1.09M) | (25.31M) | 3.43M |
| Accounts Receivables | 400K | 0 | 0 | 206K | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 20.29M | 1.83M | (402K) | (28.86M) | (88K) |
| Other Working Capital | (1.34M) | 1.57M | (690K) | 3.35M | 3.52M |
| Other Non-Cash Items | 45.17M | 2.04M | 1.51M | 16.37M | (2.98M) |
| Operating Cash Flow | (106.32M) | (9.78M) | (14.13M) | (67.71M) | (42.98M) |
| Capital Expenditures | (26K) | 0 | 0 | 0 | (200K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (76.59M) | 0 | 0 | 0 | (34.52M) |
| Sales of Investments | 262.6M | 0 | 0 | 95M | 15M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 185.98M | 0 | 0 | 95M | (19.72M) |
| Debt Repayment | 0 | 4.3M | 6M | 0 | 7.5M |
| Common Stock Issued | 232K | 0 | 0 | 21K | 50M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 5K | 1.5M | 0 | 102.11M |
| Financing Cash Flow | 232K | 12.78M | 14.24M | 21K | 159.61M |
| Effect of Forex Changes | (896K) | 0 | 0 | 852K | (117.15M) |
| Net Change in Cash | 79M | 3M | 110K | 28.17M | (20.24M) |
| Free Cash Flow | (106.35M) | (9.78M) | (14.13M) | (67.71M) | (43.18M) |
Kalaris Therapeutics Inc
NASDAQ:KLRS
Intrinsic Alpha fair value
Locked
Current Price
$2.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.